CARE Ratings Reaffirms Vimta Labs' Debt Facilities with a Stable Outlook
Vimta Labs Ltd · Others (Uncategorized) · 03 Sept 2026, 12:36 am
CARE Ratings Reaffirms Vimta Labs' Debt Facilities with a Stable Outlook On 2nd Sep'26, CARE reaffirmed Vimta Labs' credit ratings at CARE A; Stable for long-term and CARE A1 for short-term bank facilities. The rating reflects Vimta's strong FY26 financial performance, driven by robust growth in pharmaceutical research. Total operating income reached ₹411.04 crore with impressive PBILDT and PAT margins of 35.26% and 18.86%, respectively. Vimta maintains a conservative capital structure with negligible 0.01x overall gearing and strong liquidity. Future growth is supported by a planned ₹60 crore FY27 capex targeting its upcoming Biologics segment commercialization.
Original exchange filing (PDF)
More announcements from Vimta Labs Ltd
- Transcript of the FY / Q2 - 2026-27 Earnings / Investor Call held on 30th October 2026. · 04 Nov 2026
- Incorporation of a Wholly Owned Subsidiary in the United States of America (USA). · 31 Oct 2026
- Audio Recording of the Earnings Call for Q2 FY 2026-27. · 30 Oct 2026
- Press Release - Unaudited Financial Results - 30th September 2026. · 30 Oct 2026
- Investor Presentation - Q2 Results - FY 2026-27 · 30 Oct 2026
- Vimta Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 30 Oct 2026
- Unaudited Financial Results for the 2nd Quarter and Half Year ended 30.09.2026. · 30 Oct 2026
- Unaudited Financial Results for the 2nd Quarter and Half Year ended 30.09.2026. · 30 Oct 2026
